CA
NZ
UK
AU
IND
US
Silexion Therapeutics has moved forward with a clinical investigation of its candidate SIL204 aimed at pancreatic cancer patients. This step marks a transition from preparatory activities to active patient involvement, underscoring the company’s dedication to advancing its pipeline. The trial’s rationale is anchored in …
Teva Pharmaceutical Industries posted second‑quarter revenue of $4.1 billion, a modest 1% drop in U.S. dollars and a 3% slide in local‑currency terms. The decline stemmed primarily from weaker generic sales, yet the company offset part of the shortfall with a surge in its …
Waystar Holding Corp. (NASDAQ: WAY) released its second‑quarter 2026 financial results, showing revenue of $319.7 million, an increase of 18% compared with the same period last year. The company reported earnings per diluted share of $0.43 on a non‑GAAP basis, surpassing analyst expectations. GAAP …
Novo Nordisk’s weight‑loss pipeline stumbled when trial results failed to meet expectations, and a subsequent shareholder lawsuit claimed the company misrepresented the drug’s tolerability. The market reacted sharply, erasing billions from the firm’s market value and pulling down related healthcare indexes. Investors in biotech …
Option Care Health's second quarter earnings revealed a revenue of $1,442 million, marking a 1.9% increase compared to the previous year. The company's performance not only surpassed the consensus estimate for earnings per share but also indicates solid growth momentum in a competitive healthcare …
SCWorx Corp. recently received significant news confirming its initial step toward regaining its listing status with Nasdaq. The company’s situation is somewhat bolstered by its recent performance, where shares appreciated 77.1% over the past month, providing some semblance of recovery after a rough start …
The earnings per share came in at a negative $0.21, modestly better than analyst expectations, underscoring a slight beat within the company’s guidance range. Investors now have a clearer view of a business where growth pockets coexist with operational pressures, a balance that will …
Haleon plc (LSE: HLN) held its Q2 earnings call on July 30, announcing earnings per share of $0.04 for the quarter. Despite this stable performance, investor sentiment took a hit, reflected in a 3% decline in shares to $9.97 during pre-market trading. The total …
Haleon plc (LSE: HLN) held its Q2 earnings call on July 30, announcing earnings per share of $0.04 for the quarter. Despite this stable performance, investor sentiment took a hit, reflected in a 3% decline in shares to $9.97 during pre-market trading. The total …
HealthStream Inc. (NASDAQ: HSTM) has announced key financial results amid increasing scrutiny surrounding its short interest and a recently identified cybersecurity incident. This positive earnings performance is noteworthy, considering the broader market context where some sector peers experienced significant declines. Such results could instill …
Please wait processing your request...